A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines.

Trial Profile

A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2011

At a glance

  • Drugs Daptomycin (Primary)
  • Indications Bacterial endocarditis; Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Sep 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top